Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Reck

Showing results (41-50 of 114) with videos related to

Pageof 12
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 8, 2011
Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of expertsM Reck, F Barlesi, L Crinò, et al.
ESMO Open|December 18, 2021
First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an International Expert Panel Meeting by the Italian Association of Thoracic OncologyC Gridelli, S Peters, T Mok, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 21, 2004
SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: phase III resultsM E R O'Brien, H Anderson, E Kaukel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 8, 2011
A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancerM Reck, R Kaiser, C Eschbach, et al.
Pathology Oncology Research : POR|March 11, 2014
Transforming growth factor-beta signaling leads to uPA/PAI-1 activation and metastasis: a study on human breast cancer tissuesD S Lang, S Marwitz, U Heilenkötter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 13, 2005
Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesotheliomaC Manegold, J Symanowski, U Gatzemeier, et al.
Organic & Biomolecular Chemistry|April 23, 2015
Synthesis of new carolacton derivatives and their activity against biofilms of oral bacteriaN Stumpp, P Premnath, T Schmidt, et al.
The European Respiratory Journal|February 17, 2006
Efficacy of a toxicity-adjusted topotecan therapy in recurrent small cell lung cancerR M Huber, M Reck, H Gosse, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 3, 2021
Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up<sup>☆</sup>S Popat, P Baas, C Faivre-Finn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 7, 2010
Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding studyM Ranson, M Reck, A Anthoney, et al.
Pageof 12

Showing results (41-50 of 114) with videos related to

Sort By:
Pageof 12
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 8, 2011
Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of expertsM Reck, F Barlesi, L Crinò, et al.
ESMO Open|December 18, 2021
First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an International Expert Panel Meeting by the Italian Association of Thoracic OncologyC Gridelli, S Peters, T Mok, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 21, 2004
SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: phase III resultsM E R O'Brien, H Anderson, E Kaukel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 8, 2011
A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancerM Reck, R Kaiser, C Eschbach, et al.
Pathology Oncology Research : POR|March 11, 2014
Transforming growth factor-beta signaling leads to uPA/PAI-1 activation and metastasis: a study on human breast cancer tissuesD S Lang, S Marwitz, U Heilenkötter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 13, 2005
Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesotheliomaC Manegold, J Symanowski, U Gatzemeier, et al.
Organic & Biomolecular Chemistry|April 23, 2015
Synthesis of new carolacton derivatives and their activity against biofilms of oral bacteriaN Stumpp, P Premnath, T Schmidt, et al.
The European Respiratory Journal|February 17, 2006
Efficacy of a toxicity-adjusted topotecan therapy in recurrent small cell lung cancerR M Huber, M Reck, H Gosse, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 3, 2021
Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up<sup>☆</sup>S Popat, P Baas, C Faivre-Finn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 7, 2010
Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding studyM Ranson, M Reck, A Anthoney, et al.
Pageof 12